Navigation Links
Target of diabetes type 1 identified,,

Researchers have identified a set of cells in the pancreas that are targeted by the white blood cells// and cause diabetes type 1.

The researchers from University of Colorado at Denver and Health Sciences Center says their research is likely to change the study of diabetes autoimmunity and may also change the way other autoimmune diseases are studied.

Diabetes type 1 is a metabolic disorder that happens due to rising levels of sugar in the blood, and mostly is due to defects in insulin secretion, insulin function or both. Type 1 diabetes is caused when specific cells that produce insulin in the pancreas are destroyed.

Previously it was thought that these cells might be of different varieties that exist at different locations in the pancreas. The new research suggests that these cells that gets destroyed are nothing but parts of the insulin itself, a peptide called B:9-23. The new concept of single target leads to possibilities that targeting this single peptide should cause the diabetes to be under control.

The research also brings to light the importance of insulin in the study of diabetes, and that of the insulin gene in causing diabetes across the generations.

The study is published in the current edition of journal Nature.

Reference: University of Colorado at Denver and Health Sciences Center, news release, May 2005
'"/>




Page: 1

Related medicine news :

1. Target for obesity treatment
2. Gel Offers A More Targeted Approach
3. In Search Of A New Drug To Target Cholesterol
4. In Search Of A New Drug To Target Cholesterol
5. Gene Target For Tuberculosis Identified
6. New Vaccine Targeted At Effective Treatment Against Tuberculosis
7. Novel Technique For Targeting Small-Cell Lung Cancer
8. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
9. Doctors, Pharma Companies Targeted By CBI Raids
10. Research Targets treatment for dementia and brain injuries
11. Cancer Treatments Fall Short Of Targets
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology: